A股異動丨天山生物(300313.SZ)再飆升13.25% 月內漲幅已達135%
格隆匯8月26日丨五連板的天山生物(300313.SZ)再飆升13.25%,報12.65元,月內累計漲幅已達135%,自從本週一實行創業板20%漲跌幅限制以來更是啟動暴走模式。根據農業農村部對全國500個集貿市場監測,自6月份以來,牛肉價格已經連續9周環比上漲。牛肉價格飆升的背後,我國牛養殖相關企業數量上半年也出現了巨大的增長。天山生物昨日發佈澄清公告稱,近期媒體報道牛肉價格持續走高。公司全資子公司通遼天山牧業有限公司從事肉牛育肥業務,該公司成立於2020年5月,經營時間較短,截至目前存欄量育肥牛596頭,尚未出欄,未對公司收入和利潤產生貢獻。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.